A Study of the Safety and Effectiveness of Oxazyme in Patients with Hyperoxaluria

Overview

About this study

The purpose of this study is to evaluate the safety and effectiveness of oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) to degrade food-borne oxalate and prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and therefore decrease oxalate excretion in the urine.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

This study has been completed

Inclusion Criteria

  • Roux-en-Y gastric bypass hyperoxaluric Calcium oxalate (CaOx) stone subjects or Idiopathic hyperoxaluric CaOx stone subjects
  • Must have or had radio-opaque stones present on x-ray, or a history consistent with the passage of a stone, or stone surgery, or Extracorporeal Shock Wave Lithotripsy (ESWL) in the last 5 years
  • Hyperoxaluria Ox/Cr ratio ≥36 mg/g
  • Must be able to provide written informed consent
  • Must be able to urinate reliably into a collection vessel to measure urine volume
  • May take drugs for the prevention of stone disease, including pyridoxine, thiazides, citrate supplements and allopurinol, as long as there have been no changes in these medications for at least 3 months

Exclusion Criteria

  • Primary hyperoxaluria
  • Use of Oxadrop, Oxabsorb, or other therapies affecting oxalate absorption from the gut, other than stable doses of calcium
  • Pregnancy
  • A negative pregnancy test prior to enrollment 
  • Must practice some form of birth control during the trial
  • On an unstable dose of any other drugs for the prevention of stone disease (i.e., pyridoxine, citrate supplements. etc.)
    • Should have been on a stable dose for at least 3 months prior to randomization

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions